HEART TEST LABORATORIES INC (HSCS) 1.26 -0.14 (-10%)
1.26 -0.14 (-10%)
US42254E1047 - Common Stock
Fundamental Rating
Overall HSCS gets a fundamental rating of 2 out of 10. We evaluated HSCS against 221 industry peers in the Health Care Equipment & Supplies industry. HSCS has a bad profitability rating. Also its financial health evaluation is rather negative. HSCS is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
The profitability ratios for HSCS are negative, so there is not much use analyzing them.
HSCS's Return On Assets of -86.73% is worse than the rest of the industry. The industry average Return On Assets is -19.67%. 84% of the industry peers have a better Return On Assets.
HSCS has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for HSCS.
VS Industry
ROA (-86.73%) VS Industry: 16% outperformed.
-771.54
117.69
Valuation
Valuation Rating
When comparing the current price to the book value of HSCS, we can conclude it is valued correctly. It is trading at 3.57 times its book value.
Compared to an average industry price book ratio of 2.62, HSCS is valued in line with its industry peers.
HSCS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry
Price/Book (3.57) VS Industry: 43% outperformed.
1,098.53
0.06
Growth
Growth Rating
HSCS is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 11.57% yearly.
Based on estimates for the next 5 years, HSCS will show a very strong growth in Revenue. The Revenue will grow by 1431.55% on average per year.
The earnings per share for HSCS have decreased strongly by -92.26% in the last year.
The Revenue for HSCS has decreased by -43.87% in the past year. This is quite bad
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | N/A | N/A | -92.26% | -93.14% | -85.61% | -83.48% | 11.57% |
| Revenue | N/A | N/A | -43.87% | -78.71% | 419.35% | 719.41% | 1431.55% |
Health
Health Rating
HSCS has a Current Ratio of 3.53. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
HSCS has a Quick Ratio of 3.09. This indicates that HSCS is financially healthy and has no problem in meeting its short term obligations.
HSCS has a Current Ratio comparable to the industry average, which is at 3.69.
The Quick Ratio is in line with the industry averages, which is at 2.91.
Compared to an average industry Debt to Equity Ratio of 0.09, HSCS is more dependent on financing than its industry peers.
HSCS has an Altman-Z score of -13.72. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
Compared to an average industry Altman-Z score of 1.87, HSCS is in worse financial state than most of its industry peers. 92% of its industry peers have a better Altman-Z score.
HSCS has a very weak Piotroski-F score of 1.00. This is an indication of health and profitability issues for HSCS.
VS Industry
Debt/Equity (0.35) VS Industry: 32% outperformed.
336.87
0.00
Quick Ratio (3.09) VS Industry: 53% outperformed.
0.06
31.22
Current Ratio (3.53) VS Industry: 47% outperformed.
0.13
31.22
Altman-Z (-13.72) VS Industry: 8% outperformed.
-105.06
71.69
Dividend
Dividend Rating
No dividends for HSCS!.
HEART TEST LABORATORIES INC1.26
NASDAQ:HSCS (12/8/2022, 7:00:02 PM)-0.14 (-10%)
| GICS Sector | Health Care | ||
| GICS IndustryGroup | Health Care Equipment & Services | ||
| GICS Industry | Health Care Equipment & Supplies | ||
| Earnings (Last) | 09-23 2022-09-23/bmo | Earnings (Next) | 12-13 2022-12-13/bmo |
| Ins Owners | 10.91% | Inst Owners | N/A |
| Market Cap | 10.30M | Analysts | 82.5 |
| PE | N/A | Fwd PE | N/A |
| PEG (NY) | N/A | PEG (5Y) | N/A |
| P/S | 716.75 | P/B | 3.57 |
| EV/EBITDA | N/A | ||
| Dividend Yield | N/A | Dividend Growth | N/A |
| DP | N/A | Ex-Date | N/A |
| EPS 1Y | -92.26% | EPS 3Y | N/A |
| EPS 5Y | N/A | EPS growth Q2Q | -208.44% |
| EPS Next Y | -93.14% | EPS Next 2Y | -85.61% |
| EPS Next 3Y | -83.48% | EPS Next 5Y | 11.57% |
| Revenue growth 1Y | -43.87% | Revenue growth 3Y | N/A |
| Revenue growth 5Y | N/A | Revenue growth Q2Q | -57.22% |
| Revenue Next Year | -78.71% | Revenue Next 2Y | 419.35% |
| Revenue Next 3Y | 719.41% | Revenue Next 5Y | 1431.55% |
| Current Ratio | 3.53 | Quick Ratio | 3.09 |
| Altman-Z | -13.72 | F-Score | 1 |
| Debt/Equity | 0.35 | WACC | 9.36% |
| ROIC/WACC | N/A | ||
| ROA | -86.73% | ROE | N/A |
| ROICexgc | N/A | ROIC | N/A |
| PM | N/A | OM | N/A |
| Asset Turnover | 0 | ||
Fundamental Stock Screener Links
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA